title: [Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use].
abstract: OBJECTIVE
  To evaluate the results obtained with the combined use of nab-paclitaxel and gemcitabine in the treatment of patients with metastatic pancreatic adenocarcinoma.
  
  
  METHODS
  Retrospective observational study. Patients treated with nab-paclitaxel and gemcitabine between January of 2013 and January of 2014 were selected. Demographical and clinical data were gathered.
  
  
  RESULTS
  15 patients (mean age 59,4 ± 10,3 years) were included. All patients received the combination of nab-paclitaxel and gemcitabine in first-line metastatic disease. Nine received adjuvant treatment before the disease was metastatic. The median progression-free survival rate with combined nab-paclitaxel and gemcitabine was 5,6 months (95% CI: 4,44 - 8,03). In two patients the treatment was stopped due to toxicity.
  
  
  CONCLUSIONS
  The treatment with nab-paclitaxel and gemcitabine in our patients resulted in progression-free survival rates similar to those published in clinical trials with good treatment tolerability.
authors.affiliation: Servicio de Farmacia. Residente Farmacia Hospitalaria. Hospital General Universitario Santa Lucía, Cartagena.. elefevi@msn.com.
authors.forename: Elena
authors.initials: E
authors.lastname: Ferris Villanueva
authors.affiliation: Servicio de Farmacia. Farmacéutica Especialista Adjunta. Hospital General Universitario Santa Lucía, Cartagena.. elefevi@msn.com.
authors.forename: Mónica
authors.initials: M
authors.lastname: Martínez Penella
authors.affiliation: Servicio de Oncología. Facultativos Especialista Oncología. Hospital General Universitario Santa Lucía, Cartagena. España.. elefevi@msn.com.
authors.forename: Pablo
authors.initials: P
authors.lastname: Cerezuela Fuentes
authors.affiliation: Servicio de Farmacia. Residente Farmacia Hospitalaria. Hospital General Universitario Santa Lucía, Cartagena.. elefevi@msn.com.
authors.forename: Rocío
authors.initials: R
authors.lastname: Guerrero Bautista
authors.affiliation: Servicio de Farmacia. Residente Farmacia Hospitalaria. Hospital General Universitario Santa Lucía, Cartagena.. elefevi@msn.com.
authors.forename: Andrés
authors.initials: A
authors.lastname: García Márquez
authors.affiliation: Servicio de Farmacia. Farmacéutica Especialista Adjunta. Hospital General Universitario Santa Lucía, Cartagena.. elefevi@msn.com.
authors.forename: María Del Carmen
authors.initials: Mdel C
authors.lastname: Mira Sirvent
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000418:Albumins / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D000093542:Gemcitabine
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D003841:Deoxycytidine; D017239:Paclitaxel; D000093542:Gemcitabine